Outcome of children with relapsed or refractory neuroblastoma: A meta‐analysis of ITCC/SIOPEN European phase II clinical trials
Pediatric Blood & Cancer2016Vol. 64(1), pp. 25–31
Citations Over TimeTop 10% of 2016 papers
Lucas Moreno, Hervé Rubie, Amalia Varo, Marie‐Cécile Le Deley, Loredana Amoroso, Aurélie Chevance, Alberto Garaventa, Marion Gambart, Francisco Bautista, Dominique Valteau‐Couanet, Birgit Geoerger, Gilles Vassal, Xavier Paolettí, Andrew D.J. Pearson
Abstract
Baseline data for response rate, clinical benefit ratio, duration of treatment, PFS, and OS were provided. Two subpopulations (relapsed/refractory) were clearly distinct and should be included in the interpretation of all trials. These results should help informing the design of forthcoming studies in relapsed/refractory neuroblastoma.
Related Papers
- → Temozolomide: a novel oral alkylating agent(2001)111 cited
- → Temozolomide for the Treatment of Metastatic Melanoma: A Systematic Review(2007)141 cited
- → Effect of temozolomide on central nervous system relapse in patients with advanced melanoma(2002)104 cited
- → Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma(2008)2 cited
- → Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma(2011)